FDA Leadership Turnover and What It Means for Your Supply Chain
FDA Commissioner Marty Makary resigned this week. His deputy for biologics, Vinay Prasad, left before him. The acting commissioner is Kyle Diamantas, a lawyer who previously oversaw the agency's food division. Career staff have been departing steadily since mass layoffs reduced the agency's workforce significantly last year. And the leadership instability shows no signs of stabilizing anytime soon.
Meanwhile, a recent Jefferies analysis of the FDA's newly published complete response letters revealed something that supply chain professionals have long suspected but can now see in black and white: more than half of all FDA drug rejections cite manufacturing concerns. Forty-one percent involve product quality issues like impurities or failed stability testing.
Manufacturing is already the number one reason drugs don't get approved. And the agency responsible for evaluating that manufacturing is in the middle of an institutional crisis.
If you're running a biotech supply chain right now, these two realities are on a collision course, and it's worth thinking carefully about what that means for your programs.
The Regulatory Timeline You Planned Around May No Longer Hold
For any biotech company approaching a product approval, the PDUFA date is the anchor point for the entire commercial supply chain plan. Working backwards from that date, supply chain teams schedule validation batches, commercial manufacturing campaigns, packaging and labeling runs, shipping lane qualifications, and distribution center readiness. CMOs reserve capacity. Raw materials are ordered months in advance. Every one of these activities has lead times measured in weeks or months, and they're all sequenced against a target approval date.
Under normal circumstances, PDUFA dates are reasonably reliable. Companies can plan around them with confidence. But these aren't normal circumstances. The FDA has lost experienced reviewers. Leadership is turning over. The agency rejected Moderna's flu vaccine application earlier this year on grounds that surprised the industry, and multiple recent drug rejections have been seen as unpredictable departures from established precedent.
When the regulatory timeline becomes uncertain, the supply chain plan built around it starts to wobble. If the FDA misses a PDUFA date or extends a review cycle, the supply chain is left holding inventory that's aging on the shelf, paying for CMO capacity that's reserved but unused, and managing partners who need to reallocate their schedules. Manufactured product has a finite shelf life. CMO capacity that's been reserved and then not used still has to be paid for in many cases. And every delay introduces the risk that supply chain work needs to be partially redone to align with a new timeline.
The Inspection Bottleneck
This is the piece that supply chain leaders should be watching most closely. The FDA's ability to conduct pre-approval inspections of manufacturing sites is a critical dependency for product approvals. Even if the review of your application is proceeding on schedule, your product cannot be approved until the FDA has inspected and cleared the manufacturing site where it's being produced.
Routine CGMP inspections have already been affected by staffing reductions. Pre-approval inspections, which are more targeted and resource-intensive, are likely to be impacted as well. If the FDA doesn't have the personnel to schedule and conduct these inspections on the timelines companies are planning around, approvals will be delayed regardless of the state of the application review.
What makes this especially painful from an operational standpoint is that pre-approval inspections typically need to be conducted while there is active manufacturing of the launch product at the CMO site. The FDA wants to observe the process in action, not just review records. That means the inspection has to be coordinated with a live manufacturing campaign, which requires scheduling CMO capacity, ordering raw materials, and staffing the production run. If a PAI gets canceled or postponed at the last minute due to FDA staffing constraints, the company is left with an expensive manufacturing campaign that either runs without the inspection it was designed to support or gets scrapped and rescheduled. Neither outcome is cheap, and rebooking CMO capacity on short notice is rarely straightforward.
Manufacturing Was Already the Weak Spot
The Jefferies analysis of the FDA's published complete response letters puts a number on something many of us in supply chain have known intuitively: manufacturing and product quality are where approvals go to die. More than half of rejections cite manufacturing issues. Forty-one percent cite quality problems. These aren't edge cases. This is the primary failure mode.
That data should be a wake-up call for any biotech company approaching a regulatory submission. Your CMC package, your process validation, your stability data, your manufacturing controls: these are the areas most likely to generate questions, requests for additional information, or outright rejection. And in an FDA environment where reviewer bandwidth is constrained and institutional knowledge has been lost, the bar for what constitutes a sufficient manufacturing data package may be less predictable than it used to be.
When experienced reviewers leave and new ones step in, the consistency of review expectations can shift. What was accepted as adequate documentation under one reviewer may trigger additional questions from another. That's not a criticism of the people doing the work. It's a natural consequence of losing institutional continuity at the scale the FDA has experienced over the past year.
Post-Approval Changes Get Harder Too
The impact isn't limited to companies approaching their first approval. Any company with a marketed product that needs to make a manufacturing change, whether that's a site transfer, a process modification, or a new raw material supplier, needs FDA review and in many cases approval of a supplement to their application.
In a fully staffed FDA, these supplements are reviewed on established timelines. In the current environment, those timelines are less predictable. For supply chain teams managing tech transfers, CMO transitions, or post-approval process improvements, this means longer periods of uncertainty and potentially longer periods where you're running parallel operations at two sites while waiting for the supplement to be approved.
Running dual manufacturing operations is expensive. Maintaining two sets of validated processes, two sets of quality agreements, two supply chains, while waiting for regulatory clearance to consolidate, is a financial burden that most companies haven't budgeted for.
How This Is Changing the Way We Plan
The instinct in an uncertain regulatory environment is to wait for clarity before acting. That's understandable. But in my experience, the companies that navigate these periods best are the ones that start adjusting before they're forced to.
Timelines are getting wider. Supply chain plans that treat a PDUFA date as fixed are starting to feel fragile. The teams I'm working with are stress-testing what happens if an approval slides three months, or six, and making sure their CMO contracts and capacity reservations have enough flexibility to absorb that kind of shift without incurring excessive penalties or losing their manufacturing slot entirely.
Conversations with CMOs are changing too. Manufacturing partners are navigating the same uncertainty. They have other clients whose timelines are also shifting. The companies that are communicating early about the possibility of schedule changes are giving themselves more options when adjustments need to be made.
Inspection planning is getting more conservative. For companies approaching a pre-approval inspection, the assumption that historical inspection timelines will hold is becoming harder to rely on. That means building more contingency into launch plans and coordinating closely with CMOs to ensure manufacturing campaigns can be flexed if the inspection date moves.
And the manufacturing data package is getting more attention than ever. Given that manufacturing is the number one reason for FDA rejections, this was always the area that deserved the most rigor. In the current environment, where reviewer consistency may be less predictable, the teams I see positioning themselves best are the ones treating over-preparation as the default.
Uncertainty as the Operating Condition
The pharmaceutical industry has operated for decades within a regulatory framework that, whatever its imperfections, was reasonably predictable. Companies could plan around established review timelines, inspection schedules, and communication cadences with the agency. That predictability is what allowed supply chains to be optimized, timelines to be tightened, and inventory levels to be minimized.
That predictability is eroding. The cumulative effect of staffing reductions, leadership departures, unpredictable review decisions, and now the loss of the commissioner himself is degrading the FDA's capacity to operate at the pace and consistency industry has relied on.
The regulatory environment will eventually stabilize. New leadership will be confirmed. Staff will be rebuilt. Institutional knowledge will recover. But that process will take years, and in the meantime, supply chains need to operate in the uncertainty as it exists today. The companies that plan for that reality, rather than hoping for a return to normal, will be the ones best positioned to get their therapies to patients on time.
Verant Consulting Group helps biotech companies build supply chain strategies that hold up in uncertain environments, from regulatory planning and CMO management through commercial launch. If you're navigating timeline uncertainty and need help stress-testing your supply plan, let's talk.